Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Orthopaedic Surgery

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/os.12307PMID 28276638PMCID PMC6584087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

  2016cited by this paper
• Projection of osteoporosis-related fractures and costs in China: 2010–2050

  2015cited by this paper
• Risk of atypical femoral fracture during and after bisphosphonate use

  2015cited by this paper
• The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT)

  2015cited by this paper
• Bone Health and Osteoporosis.

  2015cited by this paper
• Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.

  2015cited by this paper
• Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

  2014cited by this paper
• Calcium Supplementation: Is Protecting Against Osteoporosis Counter to Protecting against Cardiovascular Disease?

  2014cited by this paper
• RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

  2014cited by this paper
• Risk of atypical femoral fracture during and after bisphosphonate use.

  2014cited by this paper
• A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

  2013cited by this paper
• The safety of osteoporosis medication.

  2013cited by this paper
• Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

  2013cited by this paper
• Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis

  2013cited by this paper
• Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.

  2013cited by this paper
• Spinal Trauma in Mainland China From 2001 to 2007: An Epidemiological Study Based on a Nationwide Database

  2012cited by this paper
• Rapidly increasing rates of hip fracture in Beijing, China

  2012cited by this paper
• Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

  2012cited by this paper
• The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)

  2011cited by this paper
• GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

  2011cited by this paper
• Osteoporosis treatments and adverse events

  2009cited by this paper
• Adverse effects of bisphosphonates: implications for osteoporosis management.

  2009cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Non-compliance: the Achilles' heel of anti-fracture efficacy

  2007cited by this paper
• Strategies for the prevention and treatment of osteoporosis during early postmenopause.

  2006cited by this paper
• Health spending rising faster than GDP in most rich countries

  2006cited by this paper
• Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

  2002cited by this paper
• Bone health and osteoporosis.

  2000cited by this paper
• The prevention and treatment of osteoporosis.

  1993cited by this paper
• The prevention and treatment of osteoporosis.

  1992cited by this paper
• [A Survey of Exact Inference for Contingency Tables]: Rejoinder

  1992cited by this paper

• Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients

  2025cites this paper
• Comparing the efficacy of teriparatide and bisphosphonates in osteoporotic patients undergoing thoracolumbar spinal fusion: a meta-analysis

  2025cites this paper
• Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.

  2024cites this paper
• Effects of Bazedoxifene/Vitamin D Combination Therapy on Serum Vitamin D Levels and Bone Turnover Markers in Postmenopausal Women with Osteopenia: A Randomized Controlled Trial

  2023cites this paper
• Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools

  2023cites this paper
• Optimization of the dosage regimen of zoledronic acid with a kinetic-pharmacodynamic model and exposure-response analysis

  2023cites this paper
• Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.

  2023cites this paper
• Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis

  2023cites this paper
• Percutaneous kyphoplasty combined with zoledronic acid for the treatment of primary osteoporotic vertebral compression fracture: a prospective, multicenter study

  2022cites this paper
• Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses

  2022cites this paper
• Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis

  2021cites this paper
• Effectiveness and safety of percutaneous kyphoplasty combined with zoledronic acid in treatment of osteoporotic vertebral compression fractures: a meta-analysis

  2021cites this paper
• Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

  2021cites this paper
• Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

  2021cites this paper
• Zoledronic acid and bone health in older adults with cognitive impairment

  2021cites this paper
• The Effect of Daily Teriparatide versus One-Time Annually Zoledronic Acid Administration After Transforaminal Lumbar Interbody Fusion in Osteoporotic Patients

  2021cites this paper
• The efficacy and safety of bisphosphonates for osteoporosis in women older than 65 years: a meta-analysis.

  2020cites this paper
• Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion

  2020cites this paper
• Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid

  2020influential citation
• Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women

  2019cites this paper
• [Risedronate inhibits rat bone marrow adipogenesis and reduces RANKL expression in adipocytes].

  2019cites this paper
• East meets West: current practices and policies in the management of musculoskeletal aging

  2019cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper